|Ms. Anne Wojcicki||Co-Founder, CEO, Pres & Director||55.12k||N/A||N/A|
|Mr. Steven J. Schoch||Chief Financial and Accounting Officer||582.83k||N/A||1959|
|Ms. Kathy L. Hibbs Esq., J.D.||Chief Admin. Officer||558.53k||N/A||1964|
|Dr. Kenneth J. Hillan Ch.B., M.B.||Chief Therapeutics Officer||557.62k||N/A||1961|
|Dr. Joseph R. Arron M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Dr. Wade Walke||VP of Investor Relations||N/A||N/A||1966|
|Ms. Jacquie Cooke Haggarty J.D.||Gen. Counsel & Privacy Officer||N/A||N/A||N/A|
|Ms. Katie Watson||VP of Communications||N/A||N/A||1978|
|Mr. Fred Mark Kohler||VP of People||N/A||N/A||1967|
|Mr. Mike Polcari||VP & Chief Architect||N/A||N/A||1981|
23andMe Holding Co. operates as a consumer genetics and research company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize promising drugs. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. The company was founded in 2006 and is headquartered in Sunnyvale, California.
23andMe Holding Co.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.